Focused On-demand Library for Zinc finger and BTB domain-containing protein 16

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q05516

UPID:

ZBT16_HUMAN

Alternative names:

Promyelocytic leukemia zinc finger protein; Zinc finger protein 145; Zinc finger protein PLZF

Alternative UPACC:

Q05516; Q8TAL4

Background:

Zinc finger and BTB domain-containing protein 16, also known as Promyelocytic leukemia zinc finger protein, plays a crucial role in transcriptional repression, myeloid maturation, and tissue differentiation. It functions as a probable substrate-recognition component of an E3 ubiquitin-protein ligase complex, facilitating the ubiquitination and proteasomal degradation of target proteins.

Therapeutic significance:

The protein is implicated in Skeletal defects, genital hypoplasia, and impaired intellectual development, a disorder marked by intellectual disability and craniofacial dysmorphism. Understanding the role of Zinc finger and BTB domain-containing protein 16 could open doors to potential therapeutic strategies.